RE:RE:RE:BTD applicationThanks Enriquesuave, a pretty good increase in the pace of newly treated may be the nicest surprise in this update. That is a validation far more important than an uptick in the stock price.
enriquesuave wrote: Also a nice 9 patients have been treated since last MD&A in August. Pace of treatments seems to be picking up. August was 42 patients plus 3 from PH1 for total of 45 Now it's 51 plus 3 for total of 54. The 7 pending from August all seem to be CR as numbers went from 19 CR to 26 CR patients. Can't get any better. IMHO
enriquesuave wrote: 7 out of 7 newly treated patients seem to be CR at 90 days. In August 19 out of 38 evaluable patients were CR. Today 26 out of 43 evaluable patients are CR. Awesome improvements.IMO
Aug 38 evaluable patients:
19 CR patients = 50% CR.
6 PR patients = 16 % CR
Total =66% responders
Nov. 43 evaluable patients
26 CR patients = 60.4%
7 PR patients = 16.3%
Total responders = 77%
If we disgard 5 patients who were severely undertreated and dropped out of trial early before 2nd treatment , plus patient who died of unrelated Heart failure, then we could count 6 patients less. ( that would still leave us with 7 undertreated patients in our data, but more realistic). That would be 26 CR out of 37, or 70.3% CR at 90 days, plus 7 out of 37, or 19% PR. For a realistic total responders at 89.2%. ( includes 7 undertreated patients). Total responders 26+7= 33 patients out of 37. I'm speculating on what our data could look like without initial 12 undertreated patents. Let's get AA in 2023 please. All IMHO